NanoVibronix UroShield Product Receives Full Reimbursement in United Kingdom
NanoVibronix (Nasdaq: NAOV) has announced that its UroShield actuators are eligible for reimbursement on NHS Prescription Services’ Drug Tariff from November 1, 2023. Drug Tariff provides for full reimbursement of UroShield actuators by the NHS effective November 1.
UroShield is a disposable ultrasound device designed to reduce biofilm by generating low frequency low intensity ultrasonic energy throughout the catheter.
Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, “Achieving Drug Tariff listing is a clear step towards broader distribution of UroShield and increasing sales. We are already experiencing an uptick in demand since reimbursement became effective on November 1. Our UroShield products have demonstrated the safety, quality and positive patient outcomes necessary to achieve Drug Tariff listing, and we are confident that by increasing patient access through reimbursement, practitioners will achieve improved outcomes for their patients.”
Auriol Lawson, Managing Director of Peak Medical Limited, commented, “We are delighted to work with NanoVibronix to offer its UroShield products to a broader population in the U.K. now that Drug Tariff reimbursement has become effective. UroShield has proven to be effective and there is a population of patients that could greatly benefit from using the device.”
Highlights
NanoVibronix has also announced it has received a stocking order from its U.K. distribution partner, Peak Medical Limited, to stock products in anticipation of a significant increase in demand. The company has already shipped products for this order.
Clinicians in the UK can now prescribe the UroShield system and patients receive full coverage from the National Health Service (NHS).
Biofilms play a significant role in the development of catheter-associated urinary tract infections (CAUTIs) and can promote infections and catheter blockages. The NIH estimates that around 12% of patients who have a catheter inserted for 30 days will develop a CAUTI.
About NanoVibronix
NanoVibronix, Inc. (Nasdaq: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company’s primary products include PainShield® and UroShield®, which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.
